The present invention relates to inhibitors of tissue transglutaminase for use in the inhibition of angiogenesis in a subject. In particular, the invention provides compounds of Formula I for use in the treatment and/or prevention of angiogenic diseases and disorders of the eye, such as diabetic retinopathy and age-related macular degeneration (AMD). The invention further provides methods for inhibiting angiogenesis in a subject.
|Patent number||GB 1107576.9|
|Publication status||Published - 6 May 2011|